---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105010"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:08:24.917366+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Janux Q2 net loss $33.9M; cash $996M; Merck milestone $10M triggered

## Summary
- Cash and short-term investments $996.0M at June 30, 2025, vs $1.03B at Dec 31, 2024.
- R&D expenses $34.7M (Q2 2025) vs $14.9M (Q2 2024); net loss $33.9M vs $6.0M.
- First patient dosed in lead Merck collaboration program triggered $10M milestone payment.
- Enrollment ongoing for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected H2 2025.
- R&D Day highlighted preclinical PSMA-TRACIr, TROP2-TRACTr, and CD19-ARM programs.

## SEC filing metadata
- accession: 0000950170-25-105010
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017025105010/0000950170-25-105010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017025105010/janx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105010
- JSON: https://secwatch.observer/filing/0000950170-25-105010.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.